This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Gallen, I. Search for Related Content Social Bookmarking                         What's this?

Review: The evolution of insulin treatment in type 1 diabetes: the advent of analogues

Diabetes Centre, Wycombe Hospital, High Wycombe, Buckinghamshire, HP11 2TT, UK, ian.gallen{at}sbucks.nhs.uk

Treating patients with type 1 diabetes to near-normal glycaemic levels significantly reduces the risk of microvascular complications and improves patient outcomes. Consequently, achieving and maintaining optimal glycaemic control is a key therapeutic aim and clear guidance regarding glycaemic targets now exists. The challenge is to achieve this level of control in routine clinical practice whilst minimising the treatment-related adverse events of hypoglycaemia and weight gain. The development of both rapid- and long-acting insulin analogues offers the potential to meet this challenge, with results from clinical trials indicating that analogue insulins have therapeutic benefits over older insulin preparations. However, it is important to see if these benefits can be repeated in non-clinical trial patient populations and, therefore, this article summarises the results from prospective audits of introducing insulin lispro and insulin glargine into routine clinical practice in patients with type 1 diabetes.

Key Words: insulin analogues • Iispro • glargine • type 1 diabetes.

References

• Diabetes Control and Complications Trial Research Group. Effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus: Diabetes Control and Complications Trial. J Paediatr 1993;125:177-88.[Web of Science]
• Leese GP, Wang J., Broomhall J. et al. Frequency of severe hypoglycemia requiring emergency treatment in type 1 and type 2 diabetes: a population-based study of health service resource use. Diabetes Care 2003;26:1176-80.[Abstract/Free Full Text]
• Owens DR, Zinman B., Bolli GB Insulins today and beyond. Lancet 2001;358:739-46.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Lepore M., Pampanelli S., Fanelli C. et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 2000;49:2142-8.[Abstract/Free Full Text]
• Home PD, Lindholm A., Riis A. Insulin aspart vs. human insulin in the management of long-term blood glucose control in Type 1 diabetes mellitus: a randomized controlled trial. Diabetic Medicine 2000;17:762-70.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Anderson JH, Jr., Brunelle RL, Koivisto VA et al. Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin-analog treatment. Multicenter Insulin Lispro Study Group. Diabetes 1997;46:265-70.[Abstract]
• Chatterjee S., Gallen IW, Sandler L. 2-year prospective audit of the effect of the introduction of insulin lispro in patients with specific clinical indications. Diabetes Care 1999;22:1226-7.[Free Full Text]
• Owens D., Griffiths S. Insulin glargine (Lantus). Int J Clin Pract 2002;56:460-6.[Web of Science][Medline] [Order article via Infotrieve]
• Rosenstock J., Park G., Zimmerman J., U.S. Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group. Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. Diabetes Care 2000;23:1137-42.[Abstract/Free Full Text]
• Ratner RE, Hirsch IB, Neifing JL et al. Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. Diabetes Care 2000;23:639-43.[Abstract/Free Full Text]
• Raskin P., Klaff L., Bergenstal R. et al. A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes. Diabetes Care 2000;23: 1666 -71. HI[Abstract/Free Full Text]
• Pieber TR, Eugene-Jolchine I., Derobert E., The European Study Group of HOE 901 in type 1 diabetes. Efficacy and safety of HOE 901 versus NPH insulin in patients with type 1 diabetes. Diabetes Care 2000;23:157-62.[Abstract]
• Ashwell S., Bilous R., Heller S., Hepburn D., Home P. Improvement in overall blood glucose control with insulin glargine plus insulin lispro in comparison with NPH insulin plus unmodified human insulin in people with Type 1 diabetes. Diabetologia 2003;A784.
• Vague P., Selam JL, Skeie S. et al. Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart. Diabetes Care 2003;26:590-6.[Abstract/Free Full Text]
• Hermansen K., Madsbad S., Perrild H., Kristensen A., Axelsen M. Comparison of the soluble basal insulin analog insulin detemir with NPH insulin: a randomized open crossover trial in type 1 diabetic subjects on basal-bolus therapy. Diabetes Care 2001;24:296-301.[Abstract/Free Full Text]
• Danne T., Lupke K., Walte K., Von Schetz W., Gall MA Insulin detemir is characterized by a consistent pharmacokinetic profile across age-groups in children, adolescents, and adults with type 1 diabetes. Diabetes Care 2003;26:3087-92.[Abstract/Free Full Text]
• Gallen IW, Carter C. Prospective audit of the introduction of insulin glargine (Lantus) into clinical practice in type 1 diabetes. Practical Diabetes International 2004;21:110-14.[CrossRef]

The British Journal of Diabetes & Vascular Disease, Vol. 4, No. 6, 378-381 (2004)
DOI: 10.1177/14746514040040060301


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Gallen, I. Search for Related Content Social Bookmarking                         What's this?